Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

48.840
-1.810-3.57%
Volume:47.44M
Turnover:2.30B
Market Cap:202.44B
PE:36.07
High:50.200
Open:49.020
Low:47.820
Close:50.650
52wk High:54.450
52wk Low:28.480
Shares:4.15B
HK Float Shares:4.15B
Volume Ratio:0.86
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.354
ROE:11.38%
ROA:7.60%
PB:3.61
PE(LYR):36.07
PS:7.35

Loading ...

Wuxi Biologics (Cayman) Stock Slips 3.6% in Hong Kong

Dow Jones
·
Yesterday

WuXi Biologics' Stronger Project Backlog Could Underpin Revenue Visibility

Dow Jones
·
Yesterday

Movement Alert|WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results

Market Focus
·
Yesterday

WuXi XDC Files HKEX Next-Day Disclosure Return, Lifts Share Capital by 1,707,842 Shares

Reuters
·
Aug 28

China's Joinn Laboratories H1 Profit Jumps 1,127% on Strong Drug Demand

Reuters
·
Aug 28

Hong Kong's Frontage Holdings H1 Profit More than Doubles on Teddy Lab Acquisition

Reuters
·
Aug 28

CMB International Lifts WUXI BIO Price Target to HK$60, Maintains "Buy" Rating

Stock News
·
Aug 28

Biocytogen Pharmaceuticals H1 Revenue up 51.6%

Reuters
·
Aug 27

Movement Alert|WUXI BIO Declines 3.05% in Regular Trading, Profit-Taking After Strong Mid-Year Results Triggers CXO Sector Pullback

Market Focus
·
Aug 27

VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds

Reuters
·
Aug 26

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Movement Alert|WUXI BIO Rises 4.02% in Regular Trading, Strong Interim Results and Raised Full-Year Guidance Fuel Rally

Market Focus
·
Aug 26

WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?

Simply Wall St.
·
Aug 26

WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme

Reuters
·
Aug 25

WuXi Biologics Reports Strong Profitable Growth in H1 2026

THOMSON REUTERS
·
Aug 25

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis

Stock News
·
Aug 25

WuXi Bio Posts Robust H1 2026: Revenue Hits RMB 11.79 Billion, Adjusted Gross Margin Widens to 48.4%; Raises FY Growth Guidance

Bulletin Express
·
Aug 25

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25